Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Dose-Escalation Study of LX102 Gene Therapy for Neovascular Age-Related Macular Degeneration (nAMD)

Authors not listed

Innostellar Biotherapeutics Co.,Ltd · 2023

Abstract

The goal of this study is to evaluate the safety and efficacy of LX102 gene therapy for nAMD.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-15 MST

Cite this

APA
Anonymous. (2023). A Dose-Escalation Study of LX102 Gene Therapy for Neovascular Age-Related Macular Degeneration (nAMD). <em>Innostellar Biotherapeutics Co.,Ltd</em>. https://clinicaltrials.gov/study/NCT06198413
Vancouver
Anonymous. A Dose-Escalation Study of LX102 Gene Therapy for Neovascular Age-Related Macular Degeneration (nAMD). Innostellar Biotherapeutics Co.,Ltd. 2023.
BibTeX
@misc{anon2023ADoseE, title = {A Dose-Escalation Study of LX102 Gene Therapy for Neovascular Age-Related Macular Degeneration (nAMD)}, author = {Anonymous}, journal = {Innostellar Biotherapeutics Co.,Ltd}, year = {2023}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings